News and Trends 27 May 2022 Blue Lake Biotechnology RSV vaccine gets FDA fast track U.S. company Blue Lake Biotechnology, Inc. has received U.S. Food and Drug Administration (FDA) Fast Track designation for its respiratory syncytial virus (RSV) intranasal vaccine. The biopharma company, a subsidiary of CyanVac LLC, develops vaccines using a parainfluenza virus 5 (PIV5)-based vector. The FDA Fast Track designation applies to BLB-201, a vaccine for the prevention […] May 27, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 May 2022 Vaccines mobilized to control monkeypox outbreak An unusual outbreak of monkeypox is causing concern worldwide in the shadow of the destructive Covid-19 pandemic. Both old and emerging vaccine technology could aid the fight against the outbreak. In the wake of the world-changing Covid-19 pandemic, the World Health Organization (WHO) is voicing alarm over another unusual outbreak, this time of the viral […] May 24, 2022 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 9 May 2022 Exosome Therapy: Borrowing from Nature’s Toolbox In just a few years, exosomes have started gaining recognition as a solution to deliver treatments safely and effectively, and as a new approach to regenerative medicine. For hundreds of millions of years, multicellular organisms have faced many of the same challenges that biotechnology is grappling with today: how best to shuttle biomolecules to and […] May 9, 2022 - 11 minutesmins - By Farhan Mitha Share WhatsApp Twitter Linkedin Email
News and Trends 20 Apr 2022 Valneva’s Covid-19 Vaccine Reaches UK Market with EU In Sights A Covid-19 vaccine developed by the French company Valneva has received the green light from the UK’s drug regulator. The EMA, meanwhile, is proving harder to convince. The UK’s relationship with the French vaccine developer Valneva has run hot and cold over the past two years. In 2020, the UK government invested in Valneva’s manufacturing […] April 20, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 1 Apr 2022 Europe Shuns Russian Covid-19 Vaccines as Ukraine War Continues In the last two years, Russian Covid-19 vaccine makers had a tough time penetrating the European market with their flagship vaccine, Sputnik V. This year, Russia’s invasion of Ukraine has likely dashed Sputnik V’s chances of reaching Europe anytime soon. Just months after the Covid-19 pandemic began, Russia was the first country to approve a […] April 1, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 22 Dec 2021 The Biggest European Biotech News of 2021 In spite of the challenges posed by the Covid-19 pandemic, the European biotech industry has emerged stronger than ever this year. These were the key moments for the sector in 2021. The year 2021 has seen skyrocketing fortunes for many European biotech players. Investment firms, for instance, raised far more funding than in 2020, which […] December 22, 2021 - 10 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2021 Valneva’s Inactivated Covid-19 Vaccine Aces Phase III Trial Last week, the French vaccine maker Valneva announced promising phase III trial results of its inactivated Covid-19 vaccine: a well-established technology that could confer broader immunity to the virus than shots currently on the market. Valneva’s vaccine candidate consists of a killed or ‘inactivated’ version of SARS-CoV-2, the virus responsible for Covid-19. The vaccine was […] October 26, 2021 - 5 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 17 Sep 2021 Cell Therapy Firm Raises €64M to Revolutionize Manufacturing This week’s €64M Series B fundraise from the French firm TreeFrog Therapeutics is the latest in a thriving movement to make the manufacture of gene and cell therapies easier and cheaper. Cell and gene therapies offer huge potential to treat a wide range of diseases including cancer, neurological, and genetic diseases. They have even shown […] September 17, 2021 - 8 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 8 Sep 2021 As J&J Vaccine Fails Phase II, the Quest for an HIV Vaccine Continues Johnson & Johnson became the latest company to have a failed vaccine trial against HIV last week. While it was a great disappointment to many, efforts continue in this space, helped by recent Covid-19 vaccine advances. HIV has been around for decades. While antiretroviral treatments have improved enormously, turning what was once a death sentence […] September 8, 2021 - 5 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 3 Aug 2021 Oral and Nasal Covid-19 Vaccines Hit Clinical Testing Oramed’s jab-free oral Covid-19 vaccine is one of many in the form of pills, powders, or sprays that may hit the market in the next few years, which could dramatically expand vaccine rollout and uptake. An Israeli team is preparing to start trials of what could be the first Covid-19 vaccine pill. The vaccine consists […] August 3, 2021 - 5 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jun 2021 Patent Waiver on Covid-19 Vaccines Splits Opinions in Biotech Industry Attempts to increase global Covid-19 vaccine coverage with a temporary patent waiver have been met with hostility from many big pharma and biotech companies, but some smaller players welcome the idea. With the Covid-19 pandemic still rampaging through many countries and new viral variants popping up with alarming regularity, scuffles over who holds intellectual property […] June 15, 2021 - 5 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
News and Trends 10 Jun 2021 The Top European Biotech Investment Rounds in May Last month saw huge biotech investment rounds dedicated to Covid-19 vaccines in Europe, including IPOs by Valneva and Vaccitech. However, a €227M (£195M) private round by the DNA sequencing giant Oxford Nanopore Technologies made the biggest splash. Last month was a difficult one for a number of public biotech companies. Biotech stock indices proved volatile […] June 10, 2021 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email